Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medmix AGCHIX:MEDXZ +1.97%66 Piotroski F-Score is 5 as of Jul. 31, 2026, which is at its 10-year median of 5.00. GuruFocus rates CHIX:MEDXZ with a GF Score™ of 66/100 and a GF Value™ of CHF9.05 (Fairly Valued). The stock has 6 warning signs investors should review. Among 2,960 Industrial Products companies, Medmix AG ranks better than 56.28% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Medmix AG has an F-score of 5 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Medmix AG's Piotroski F-Score or its related term are showing as below:
CHIX:MEDXz'
s Piotroski F-Score Range Over the Past 10 Years
Min: 4 Med: 5 Max: 9
Current: 5
During the past 8 years, the highest Piotroski F-Score of Medmix AG was 9. The lowest was 4. And the median was 5.
Medmix AG (CHIX:MEDXz) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Medmix AG Piotroski F-Score Related Terms
Medmix AG Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Medmix AG's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:MEDXZ vs GEV, ETN, PH: Piotroski F-Score Comparison
For the Specialty Industrial Machinery subindustry, Medmix AG's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medmix AG Piotroski F-Score vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Medmix AG's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Medmix AG's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Medmix AG's current Net Income (TTM) was 6.4.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Medmix AG's return on assets of this year was 0.00670719. Medmix AG's return on assets of last year was -0.00735002.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Medmix AG's current ratio of this year was 1.54333915. Medmix AG's current ratio of last year was 1.60343769.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Medmix AG's number of shares in issue this year was 41.512. Medmix AG's number of shares in issue last year was 41.41.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Medmix AG's gross margin of this year was 0.36138393. Medmix AG's gross margin of last year was 0.33002687.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Medmix AG's asset turnover of this year was 0.46950325. Medmix AG's asset turnover of last year was 0.4806317.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
1
+
0
+
0
+
0
+
1
+
0
=
5
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Medmix AG has an F-score of 5 indicating the company's financial situation is typical for a stable company.
Medmix AG (CHIX:MEDXZ) has a Piotroski F-Score of 5 as of Jul. 31, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Medmix AG and its competitors. This is near median its historical median of 5.00. Over the past decade, Medmix AG's Piotroski F-Score has ranged from 4.00 to 9.00. According to the industry distribution chart, Medmix AG ranks #1294 out of 2960 companies in the Industrial Products industry, placing it in the top 43.7%.
Is Medmix AG's Piotroski F-Score too high?
Medmix AG's current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 9.00. The Industrial Products industry median Piotroski F-Score is 5.00. Medmix AG's value of 5 is 0% at this industry median. Based on the distribution chart, Medmix AG ranks #1294 out of 2960 companies in the Industrial Products industry, which is above the industry midpoint. Overall, Medmix AG has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medmix AG's Piotroski F-Score compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Medmix AG ranks #1294 out of 2960 companies for Piotroski F-Score. This puts Medmix AG in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Medmix AG's value of 5 is 0% at this benchmark. Historically, Medmix AG's own Piotroski F-Score has ranged from 4.00 to 9.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Medmix AG has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for an Industrial Products company?
The median Piotroski F-Score among Industrial Products companies is 5.00, based on 2,960 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medmix AG's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Medmix AG and its competitors. For the Industrial Products industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medmix AG's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medmix AG stock overvalued right now?
Based on GuruFocus' analysis, Medmix AG (CHIX:MEDXZ) is currently considered Fairly Valued. The stock's GF Value™ is CHF9.05, compared to a current price of CHF8.54 — trading 5.7% below its estimated fair value. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 0% at the Industrial Products industry median of 5.00. Medmix AG's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Medmix AG (CHIX:MEDXZ), the current Piotroski F-Score is 5 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medmix AG (CHIX:MEDXZ) Overvalued in 2026?
Based on GuruFocus' analysis, Medmix AG stock appears to be undervalued.
The current stock price of CHF8.54 is trading 5.7% below its estimated GF Value™ of CHF9.05.
GuruFocus considers Medmix AG to be Fairly Valued.
Key valuation signals for CHIX:MEDXZ:
Piotroski F-Score: 5 (near median its 10-year median of 5.00)
GF Value™: CHF9.05 vs. price of CHF8.54 (5.7% below fair value)
Industry Position: 0% at the Industrial Products median (#1294 of 2960)
No single metric tells the full story. See the CHIX:MEDXZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medmix AG designs and produces high-precision delivery devices for the healthcare, consumer and industrial segments. Its segments are Healthcare, Consumer & Industrial, and Others. The Healthcare segment focuses on delivery devices for the drug delivery, surgery, and dental markets, including injection pens for subcutaneous drug delivery, surgical delivery devices, and mixing and delivery systems for the dental consumable industry. The Consumer & Industrial segment focuses on delivery devices used for industrial applications such as adhesives in construction, electronics, automotive, and aerospace, as well as consumer markets such as beauty and microbrush applications. The company operates in Europe, the Middle East and Africa, the Americas, and Asia-Pacific.
66GF Score
Get the complete analysis for CHIX:MEDXZ
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:MEDXZ has been successfully added to your 
